SCHEMBL305874

SCHEMBL305874

CCCCCCCCC=CCCCCCCCC(=O)OP(=O)(O)OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 3/20 0.55
FABP3 P05413 5/20 0.54
LPAR1 Q92633 5/20 0.53
LPAR4 Q99677 2/20 0.53
LPAR5 Q9H1C0 2/20 0.53
LPAR2 Q9HBW0 2/20 0.53
LPAR3 Q9UBY5 2/20 0.53
CES2 O00748 1/20 0.53
LPAR6 P43657 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
PLA2G4A P47712 1/20 0.52
TERT O14746 3/20 0.51
MAPT P10636 2/20 0.51
BLM P54132 2/20 0.51
HSD17B10 Q99714 2/20 0.51
FABP4 P15090 2/20 0.51
GMNN O75496 1/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27647304 1.00 ENPP2 (0.55) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL3888681 0.92 FABP3 (0.59) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL20484292 0.92 FABP3 (0.59) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL22802111 0.92 FABP3 (0.59) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL29086569 0.91 DGKA (0.50) ENPP2LPAR1LPAR4LPAR5LPAR2
SCHEMBL340006 0.87 LPAR1 (0.55) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL10478921 0.87 LPAR1 (0.55) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL28547666 0.87 LPAR1 (0.55) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL193956 0.86 LPAR1 (0.60) ENPP2FABP3LPAR1LPAR4LPAR5
SCHEMBL18123890 0.86 LPAR1 (0.60) ENPP2FABP3LPAR1LPAR4LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115485431-A Treating agent for synthetic fiber, and method for treating synthetic fiber 竹本油脂株式会社 2022-12-16 CN disclosed
CN-111764173-A Treating agent for elastic fiber and elastic fiber 竹本油脂株式会社 2020-10-13 CN disclosed
US-20130090237-A1 PTEREDIN PENTANEDIOIC DERIVATIVE BASED NANOPARTICLES MOHANTY SANAT (IN) 2013-04-11 US disclosed
US-20120077022-A1 HIERARCHICAL CHROMONIC STRUCTURES 3M INNOVATIVE PROPERTIES COMPANY 2012-03-29 US disclosed
US-8092710-B2 Hierarchical chromonic structures 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-10 US disclosed
US-7993748-B2 Multilayered chromonic structures 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-08-09 US disclosed
US-7981469-B2 Encapsulated chromonic particles 3M INNOVATIVE PROPERITES COMPANY (US) 2011-07-19 US disclosed
US-20110020540-A1 ENCAPSULATED CHROMONIC PARTICLES 3M INNOVATIVE PROPERTIES COMPANY 2011-01-27 US disclosed
US-7824732-B2 Encapsulated chromonic particles 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-11-02 US disclosed
US-7718716-B2 Chromonic nanoparticles containing bioactive compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-05-18 US disclosed
WO-2007047258-A1 CHROMONIC NANOPARTICLES CONTAINING BIOACTIVE COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-04-26 WO disclosed
WO-2007047307-A1 METHOD FOR MAKING CHROMONIC NANOPARTICLES 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-04-26 WO disclosed
US-20070086965-A1 Chromonic nanoparticles containing bioactive compounds 3M INNOVATIVE PROPERTIES COMPANY 2007-04-19 US disclosed
US-20070086964-A1 Method for making chromonic nanoparticles 3M INNOVATIVE PROPERTIES COMPANY 2007-04-19 US disclosed
US-20070042916-A1 METHODS FOR IMPROVED POWER TRANSMISSION PERFORMANCE AND COMPOSITIONS THEREFOR AFTON CHEMICAL CORPORATION 2007-02-22 US disclosed
US-20070000745-A1 METHODS FOR IMPROVED POWER TRANSMISSION PERFORMANCE AFTON CHEMICAL CORPORATION 2007-01-04 US disclosed
US-20070004603-A1 METHODS FOR IMPROVED POWER TRANSMISSION PERFORMANCE AND COMPOSITIONS THEREFOR AFTON CHEMICAL CORPORATION 2007-01-04 US disclosed
EP-1739321-A2 Methods for improved power transmission performance Afton Chemical Corporation (US) 2007-01-03 EP disclosed
EP-1739158-A2 Methods for improved power transmission performance and lubricating compositions therefor Afton Chemical Corporation (US) 2007-01-03 EP disclosed
EP-1739159-A2 Methods for improved power transmission performance and lubricating compositions therefor Afton Chemical Corporation (US) 2007-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070086965-A1 Chromonic nanoparticles containing bioactive compounds RCC1, CTRL, CASP12 ENPP2 3887/4885FABP3 1864/4885LPAR1 668/4885
US-20070086964-A1 Method for making chromonic nanoparticles CA13, CHRNA6, CA12 ENPP2 3149/4885FABP3 2000/4885LPAR1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.